Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fluoxetine + lamotrigine is a combination of two pharmaceutical drugs used together, most commonly in psychiatric practice. Fluoxetine is a selective serotonin reuptake inhibitor (SSRI) antidepressant that increases synaptic serotonin levels by inhibiting its reuptake into presynaptic neurons. Lamotrigine is an anticonvulsant and mood stabilizer that inhibits voltage-sensitive sodium channels, thereby stabilizing neuronal membranes and modulating the release of excitatory neurotransmitters such as glutamate. This combination has been reported in case studies for the treatment of conditions such as compulsive sexual behavior and may be considered in complex mood or impulse control disorders where both antidepressant and mood-stabilizing effects are desired[3]. The combination requires careful monitoring due to potential pharmacokinetic interactions (fluoxetine can increase blood levels of lamotrigine), risk of adverse effects including delirium or severe skin reactions like Stevens-Johnson syndrome[1][2][4][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on fluoxetine + lamotrigine.